Long-term clinical cohort studies have documented the importance of platelet Tau variants as early diagnosis or the prevention of neurodegenerative diseases including AD [53, 54], which is consistent with relevant results, indicating that phosphorylated Tau in plasma may be an essential biomarker in the early stage of AD [55, 56]. The gene discussed is MAPT; the disease is Alzheimer disease.